BURNING ROCK BIOTECH LTD.

Company Overview

Burning Rock Biotech Ltd. develops products in the field of precision oncology using next-generation sequencing (NGS) technology. The company offers a variety of DNA and RNA NGS panels across various cancer types, including breast, gastrointestinal, lung, prostate, thyroid, lymphoma, and pan cancers. The company’s workflow is adapted to Illumina’s platforms, including NextSeq 2000 and NextSeq 550Dx. Burning Rock’s key offerings include NGS-based therapy selection testing for late-stage cancer patients, biomarker detection and companion diagnostic development services, NGS-based cancer early detection, minimal residual disease (MRD), COVID-19 clinical testing, and clinical research services on molecular diagnostic devices. The company’s OverC test is intended for the early detection of multiple cancer types, including esophageal, liver, lung, pancreatic, and ovarian, in adults of either sex, aged 50 to 75 years old. The test demonstrated a 69.1% sensitivity and 98.9% specificity in the case-control study, THUNDER. OverC is undergoing further validation in prospective interventional (PREVENT) studies among the asymptomatic population.

Financial Highlights (FY 2025)

Company's Business Segments

• Central Laboratory : Cancer therapy selection tests
• In-hospital : Facilitate the hospitals’ procurement of laboratory equipment, Reagent Kits
• Pharma Research and Development Services : Targeted therapies and immunotherapies for various types of cancer